Cargando…
Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials
Pharmacogenetics and biomarkers are becoming normalised as important technologies to improve drug efficacy rates, reduce the incidence of adverse drug reactions, and make informed choices for targeted therapies. However, their wider clinical implementation has been limited by a lack of robust eviden...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789450/ https://www.ncbi.nlm.nih.gov/pubmed/31480618 http://dx.doi.org/10.3390/jpm9030042 |